The Trump administration is completing the final review of a Medicare Part D rule implementing a Most Favored Nation (MFN) pricing model. This regulatory change aims to align Medicare drug prices with those offered in other developed countries, affecting reimbursement for high-cost medications. Stakeholders anticipate significant policy shifts influencing drug pricing, market access, and industry negotiations within the Medicare program.